Broncus Holding Corporation (HKG:2216)

Market Cap	1.19B
Revenue (ttm)	63.16M
Net Income (ttm)	-118.87M
Shares Out	525.59M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,496,000
Average Volume	4,405,764
Open	2.060
Previous Close	2.060
Day's Range	2.040 - 2.340
52-Week Range	0.460 - 2.880
Beta	1.41
RSI	58.84
Earnings Date	Aug 29, 2025

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 200
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2216

Financial Performance

In 2024, Broncus Holding's revenue was $8.13 million, a decrease of -20.71% compared to the previous year's $10.26 million. Losses were -$15.30 million, -45.52% less than in 2023.

Financial numbers in USD